Neurogene Inc.
NGNE
$19.98
-$0.01-0.05%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 0.00 | 925.00K | 925.00K | 925.00K | 925.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.00 | 925.00K | 925.00K | 925.00K | 925.00K |
| Cost of Revenue | 68.76M | 65.14M | 60.83M | 57.66M | 52.98M |
| Gross Profit | -68.76M | -64.21M | -59.90M | -56.74M | -52.06M |
| SG&A Expenses | 26.93M | 25.53M | 22.61M | 19.00M | 16.72M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 95.69M | 90.67M | 83.44M | 76.66M | 69.70M |
| Operating Income | -95.69M | -89.75M | -82.51M | -75.74M | -68.77M |
| Income Before Tax | -84.39M | -80.87M | -75.14M | -53.25M | -47.61M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -84.39 | -80.87 | -75.14 | -53.25 | -47.61 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -84.39M | -80.87M | -75.14M | -53.25M | -47.61M |
| EBIT | -95.69M | -89.75M | -82.51M | -75.74M | -68.77M |
| EBITDA | -92.56M | -86.56M | -79.27M | -72.46M | -65.48M |
| EPS Basic | -4.32 | -4.36 | -4.29 | 78.14 | 46.67 |
| Normalized Basic EPS | -2.70 | -2.73 | -2.68 | -15.63 | -35.30 |
| EPS Diluted | -4.32 | -4.37 | -4.29 | -0.26 | -31.73 |
| Normalized Diluted EPS | -2.70 | -2.73 | -2.68 | -2.55 | -22.22 |
| Average Basic Shares Outstanding | 78.47M | 74.36M | 70.27M | 51.44M | 34.93M |
| Average Diluted Shares Outstanding | 78.47M | 74.36M | 70.27M | 68.10M | 51.59M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |